Research
Hormonal
Lowering blood pressure in Type 2 Diabetes patients reduces the risk of cerebrovascular accidents and congestive heart failure, with ACE inhibitors or ARBs recommended as first-line therapy.
Keep your blood pressure below 140/80 mmHg using ACE inhibitors or ARBs as your first medication. This is crucial for preventing strokes and heart failure in Type 2 Diabetes.
StrongSupportsVERY_HIGH confidence
several clinical investigations have shown that lowering blood pressure in patients with hypertension and diabetes reduces the risk of cerebrovascular accidents and congestive heart failure... The most up-to-date diabetes guidelines recommend an ACE-I or ARB as the first line of therapy.
Why this rating
Supported by multiple clinical investigations and guidelines.
Source
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Daniel Lorber · Diabetes Metabolic Syndrome and Obesity · 2014
DOI 10.2147/dmso.s61438
narrative_reviewCited 170×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive glucose control (targeting HbA1c <6.0-6.5%) in Type 2 Diabetes does not significantly reduce cardiovascular events and may increase mortality, whereas intensive control in Type 1 Diabetes shows a sustained legacy benefit on CV outcomes.Strong
- Lowering LDL cholesterol with statins reduces major cardiovascular events in Type 2 Diabetes patients, whereas pharmacological interventions to raise HDL cholesterol or lower triglycerides have not shown consistent beneficial effects on cardiovascular risk.Strong
- Intensive lifestyle intervention (caloric restriction + 175 min/week moderate exercise) in overweight/obese T2DM patients reduces cardiovascular risk factors and improves quality of life but does not significantly reduce major cardiovascular events compared to standard diabetes education.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →